# Acculine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acculine

- Industry: Healthcare IT
- Headquarters: Petah Tikva, Israel
- Website: www.acculine-medical.com
- Total disclosed funding: $4.2M
- Latest round: Seed (Jul 14, 2024)
- Investors on record: 2

## About

Based in Petah Tikva, Israel, and founded in 2022 by CEO Moshe Barel, CTO Benny Shani, Aharon Frimerman, and Shai Revzen, Acculine Ltd. operates as a healthcare technology company that focuses on developing advanced, non-invasive diagnostic tools to address coronary artery disease (CAD). In July 2024, Acculine Ltd. raised USD 4.2 million in seed funding co-led by new investors eHealth Ventures and Maccabi Health Services.

AccuLine offers CORA, a system designed to evaluate a patient’s risk for coronary artery disease (CAD) through a four-minute analysis of vital signs, including heart electrical activity, oxygen saturation, and respiratory phase. Utilizing AI-powered signal processing and two novel bio-signals, voltage spread and vectorcardiography (VCG), the system provides detailed insights into cardiac health. The platform features proprietary augmented waveform display technology, enabling analysis of hundreds of heartbeats. CORA is non-invasive, requires no consumables, and can be operated in diverse medical settings.

The company plans to use its proceeds from July 2024 funding to support the further development of the CORA system.

## Funding rounds

- Seed, Jul 14, 2024, $4.2M — eHealth Ventures, Maccabi Health Services

## Investors

- eHealth Ventures (https://capitalatlas.ai/funds/ehealth-ventures) — Seed
- Maccabi Health Services — Seed